<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;STK11&lt;/i&gt;</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>STK11</i></h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>STK11</i></div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Chung, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Linda H Rodgers, MGC, CGC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2026823535"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline testing of the<em> STK11 </em>(<em>LKB1) </em>gene. It does <strong>not</strong> discuss indications for testing and is not intended to replace clinical judgment in the decision to test or in the clinical care of the individual who was tested. These subjects are discussed separately [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H2057270043"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H728423939"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>An approach to reviewing a genetic test report is summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>). </p><p>Testing involves two steps: determining the genotype and interpreting the pathogenicity of the variant(s).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype</strong> – Identifies the variants in the gene(s) tested. Should be repeated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory if the results were obtained by direct-to-consumer testing or a research study and would impact clinical care (eg, positive finding, negative finding in an individual with a suspected cancer syndrome). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Determines pathogenicity of the variants identified. May require updating, especially for variants of unknown significance (VUS). (See  <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Epidemiology and genetics'</a>.)</p><p></p><p>The table provides a glossary of genetic testing terms  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1118952643"><span class="h2"><i>STK11</i> (<i>LKB1</i>) gene</span><span class="headingEndMark"> — </span>Pathogenic and likely pathogenic variants in <em>STK11</em> are associated with Peutz-Jeghers syndrome (PJS). PJS is an autosomal dominant disorder that is most often due to germline pathogenic variants in the <em>STK11 </em>(<em>LKB1) </em>gene<em> </em>encoding a serine threonine kinase mapped to chromosome 19p13.3. A germline pathogenic variant in <em>STK11,</em> a designated tumor suppressor gene, in combination with an acquired pathogenic variant in the second <em>STK11</em> allele in somatic cells, are responsible for the clinical manifestations of PJS. </p><p class="headingAnchor" id="H1347743451"><span class="h2">Disease associations</span><span class="headingEndMark"> — </span>The two characteristic manifestations of PJS are pigmented mucocutaneous macules and multiple hamartomatous gastrointestinal polyps. Individuals with PJS are also at an increased risk for both gastrointestinal and extraintestinal cancers.</p><p class="headingAnchor" id="H139399382"><span class="h3">Hamartomatous polyps</span></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal hamartomatous polyps are present in most patients with PJS. Although polyps most commonly occur in the small bowel (60 to 90 percent) and more specifically in the jejunum, they can be found throughout the gastrointestinal tract including the stomach (15 to 30 percent) and colon (50 to 64 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyps develop in the first decade of life, and symptoms usually begin between the ages of 10 and 30 years. Individuals with PJS can present with obstruction caused by intussusception or occlusion of the gastrointestinal lumen by the polyp, abdominal pain caused by infarction, anemia from acute or chronic bleeding, or extrusion of the polyp through the rectum. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hamartomatous polyps may also occur in the renal pelvis, urinary bladder, lungs, and nasopharynx.</p><p></p><p class="headingAnchor" id="H682161959"><span class="h3">Mucocutaneous pigmentation</span><span class="headingEndMark"> — </span>Mucocutaneous pigmented macules (melanin spots) are present in more than 95 percent of individuals with PJS. These pigmented macules commonly occur on the lips and perioral region, buccal mucosa, palms of the hands, and soles of the feet. Mucocutaneous pigmentation usually occurs during the first one to two years of life, increases in size and number over the ensuing years, and finally fades after puberty except those on the buccal mucosa.</p><p class="headingAnchor" id="H1380120851"><span class="h3">Cancer</span></p><p class="headingAnchor" id="H95758416"><span class="h4">Gastrointestinal</span><span class="headingEndMark"> — </span>Individuals with PJS have an increased risk of colorectal (39 percent), gastric (29 percent), small bowel (13 percent), and pancreatic cancer (11 to 36 percent). Other gastrointestinal cancers associated with PJS include cancers of the biliary tree, gallbladder, and esophagus.</p><p class="headingAnchor" id="H3791371690"><span class="h4">Extraintestinal</span><span class="headingEndMark"> — </span>Females with PJS have an increased risk of breast, ovarian (sex cord tumor with annular tubules, 20 percent of which may become malignant), endometrial, and a rare subtype of cervical (adenoma malignum) cancer. Males with PJS are at increased risk of testicular tumors (Sertoli cell tumors). Individuals with PJS are also at increased risk for lung cancer and possibly thyroid cancer.</p><p class="headingAnchor" id="H3063735395"><span class="h1">INDIVIDUALS WITHOUT CANCER</span></p><p class="headingAnchor" id="H299883186"><span class="h2">Implications of a pathogenic or likely pathogenic variant</span><span class="headingEndMark"> — </span>We consider all variants in <em>STK11</em> that are pathogenic or likely pathogenic the same for purposes of counseling and cancer risk reduction, regardless of the initial reason for testing and the family history.</p><p>Discussion should include the range of cancer risks, possible interventions for surveillance or risk reduction, and implications for at-risk family members. (See <a class="local">'At-risk relatives'</a> below.)</p><p>Counseling may require additional visits or referral to a genetic counselor, clinical geneticist, or oncologist. Acting upon genetic test results is usually not an emergency; the individual can be reassured that management decisions can be deferred until questions have been answered.</p><p>Our recommendations are largely consistent with the American College of Gastroenterology (ACG) and the National Comprehensive Cancer Network (NCCN) guidelines for surveillance and risk reduction [<a href="#rid2">2,3</a>]. The type of cancer and age of onset in a family member may also inform screening (eg, screening at an earlier age if a family member has an earlier age of onset). </p><p>In addition to an annual physical examination with a complete blood count to detect iron deficiency anemia due to occult bleeding from gastrointestinal tract polyps or cancer, several evaluations and interventions are recommended to reduce the risk of Peutz-Jeghers syndrome (PJS)-associated cancers. Use of these strategies depends on the patient's age, values, and preferences  (<a class="graphic graphic_algorithm graphicRef130038" href="/z/d/graphic/130038.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef130037" href="/z/d/graphic/130037.html" rel="external">table 3</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal tract cancer</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Baseline screening of the stomach and colon with upper endoscopy and colonoscopy at ages eight to ten years. The interval for follow-up is based on the findings. However, in the absence of polyps, follow-up screening is recommended at 18 years and then repeated every two to three years. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Baseline endoscopic screening of the small intestine with video capsule endoscopy (VCE) beginning at ages eight to ten years. The interval for follow-up is based on the findings. However, in the absence of polyps, follow-up screening is recommended at 18 years and then repeated every two to three years. Computed tomography enterography (CTE) or magnetic resonance enterography (MRE) are alternative imaging modalities for individuals with PJS in whom capsule endoscopy cannot be performed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endoscopic polypectomy for polyps larger than 0.5 cm that are detected during upper endoscopy and colonoscopy. All other small bowel polyps &gt;1 cm in size should be resected to reduce the risk of polyp-related complications (eg, anemia, bleeding, obstruction, malignancy, and need for urgent surgery).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Indications for surgery include the inability to achieve endoscopic polyp control either due to polyp size or number and the presence of neoplasia. Surgery may also be required in patients with small bowel obstruction or intussusception.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testicular tumors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annual examinations of the testicles beginning around age 10 years. If abnormalities are detected on testicular examination or if patients have signs of feminization (eg, gynecomastia), additional evaluation (eg, testicular ultrasound) is warranted. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian, endometrial, and cervical cancer</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annual physical examination for observation of precocious puberty starting at age eight years</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annual pelvic examination and Pap smear starting at age 18 to 20 years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For females with PJS, starting at age 30 years: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Clinical breast examinations and self-examinations every six months </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Breast magnetic resonance imaging (MRI) and mammography annually </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreatic cancer</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound (EUS) annually starting at age 30 to 35 years. Screening for pancreatic cancer should preferably be performed in the setting of a research protocol at an experienced center with a multidisciplinary team. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung cancer</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoid smoking. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Guidelines for screening for lung cancer do not differ from those in the general population.</p><p></p><p>Additional details and the supporting evidence are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management", section on 'Cancer screening'</a>.)</p><p class="headingAnchor" id="H1890607148"><span class="h2">Implications of a negative test</span><span class="headingEndMark"> — </span>Negative testing means no pathogenic or likely pathogenic variants were identified  (<a class="graphic graphic_algorithm graphicRef130038" href="/z/d/graphic/130038.html" rel="external">algorithm 1</a>). However, some tests only evaluate a subset of variants; pathogenic variants might be present in other parts of the gene (if testing was not comprehensive) or in other genes. </p><p class="bulletIndent1"><span class="glyph">●</span>If the familial variant in <em>STK11</em> is known and the tested individual does not have that variant, usually they can be reassured that they are not at high risk for PJS-associated cancers, with the caveats outlined above (see <a class="local">'How to read the report'</a> above). However, it is important to assess family history and other cancer risk factors to provide an individualized risk. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a familial variant in <em>STK11 </em>is not known and the results of genetic testing are negative, additional risk factors (genetic or acquired) may be present, and additional testing (with a gene panel that includes other colorectal cancer genes) and/or surveillance is based on family history and other risk factors. Referral to a clinical geneticist, oncologist, or genetic counselor may be helpful to determine optimal testing in those with a strong family history of cancer. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p></p><p class="headingAnchor" id="H3527038276"><span class="h2">Implications of a VUS</span><span class="headingEndMark"> — </span>Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history and not the VUS  (<a class="graphic graphic_algorithm graphicRef130038" href="/z/d/graphic/130038.html" rel="external">algorithm 1</a>).</p><p>New information may become available, and the testing laboratory or other resource should be consulted periodically for updates in the classification of the VUS (eg, annually).</p><p class="headingAnchor" id="H1972548545"><span class="h1">INDIVIDUALS WITH CANCER</span><span class="headingEndMark"> — </span>The implications of genetic test results should be discussed with the individual's oncologist or surgeon; in some cases, referral to a specialist in hereditary colorectal cancer syndromes may be appropriate. </p><p>The presence of a pathogenic or likely pathogenic variant in <em>STK11 </em>may impact several aspects of management, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Additional surveillance and prophylactic measures. (See <a class="local">'Implications of a pathogenic or likely pathogenic variant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling and testing of family members are also often appropriate. (See <a class="local">'Considerations for relatives'</a> below.)</p><p></p><p>For individuals with a negative test or a variant of uncertain significance (VUS) for whom there are reasons to be concerned about a genetic cause, additional genetic testing may be appropriate. The need for additional testing may be discussed with a genetic counselor, the primary oncologist, or other specialists with expertise in managing hereditary colorectal cancer syndromes. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p class="headingAnchor" id="H1478031590"><span class="h1">CONSIDERATIONS FOR RELATIVES</span></p><p class="headingAnchor" id="H181400700"><span class="h2">Preconception counseling</span><span class="headingEndMark"> — </span>Preconception counseling is appropriate for individuals with a pathogenic or likely pathogenic variant in <em>STK11</em> who are considering childbearing.</p><p>Some may elect to conceive using donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.) </p><p class="headingAnchor" id="H3079847833"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals who test positive for a pathogenic variant or likely pathogenic variant should inform their at-risk relatives about the importance of genetic counseling and possible testing. </p><p class="bulletIndent1"><span class="glyph">●</span>The risk of having inherited the variant is 50 percent for first-degree relatives. Other at-risk relatives may include aunts, uncles, nieces, nephews, and cousins. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Usually, the variant segregates on the side of the family with a history of cancer; however, if possible, it is recommended to test a parent or other relative with cancer to determine the at-risk side of the family. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing for at-risk relatives may be considered as early as eight years. Age of polyposis onset for relatives may help guide the decision of when to test. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Families facing decisions to test minors should meet with a certified genetic counselor or other health care provider with genetics expertise. If genetic testing is deferred in a child at 50 percent risk, Peutz-Jeghers syndrome (PJS) screening is recommended until informative genetic testing is obtained  (<a class="graphic graphic_algorithm graphicRef130038" href="/z/d/graphic/130038.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef130037" href="/z/d/graphic/130037.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a> and <a class="local">'Implications of a pathogenic or likely pathogenic variant'</a> above.)</p><p></p><p class="headingAnchor" id="H3211127905"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H2899309448"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Peutz-Jeghers syndrome (PJS) and associated cancers:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Manifestations and management – (See  <a class="medical medical_review" href="/z/d/html/2533.html" rel="external">"Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variant classification – (See  <a class="medical medical_review" href="/z/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression", section on 'Clinical classification of pathogenicity'</a>.) </p><p class="bulletIndent2"><span class="glyph">•</span>Terminology – (See  <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counseling – (See  <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p><p class="headingAnchor" id="H249712071"><span class="h2">Locating a genetics expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=129269" target="_blank">ACMG</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=129269" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>National Institutes of Health (NIH) Cancer Genetics <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=129269" target="_blank">Services Directory</a> </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on October 24, 2022).</li><li><a class="nounderline abstract_t">Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110:223.</a></li></ol></div><div id="topicVersionRevision">Topic 129269 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on October 24, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645574" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
